EmeraNova Expands Product Reach into Acute Care
The rebranding of BioLab Holdings signals a shift for surgical and outpatient operators seeking new membrane product suppliers.
Updated on Oct. 15, 2026 in Healthcare
BioLab Holdings has rebranded to EmeraNova as part of a strategic push to expand its amniotic membrane product portfolio into new care settings. The company, headquartered in Phoenix, aims to move beyond chronic wound care into acute care and hospital outpatient departments.
Why it matters
The rebrand signals a shift toward broader clinical applications in surgery, sports medicine, and aesthetics, supported by a proprietary eight-stage development model. This expansion seeks to capture new market share as the firm leverages its AATB-accredited infrastructure.
The company completed four clinical trials and three peer-reviewed retrospective studies in 2026. These efforts anchor its eight-stage toolbox model, which guides the commercialization of its amniotic membrane portfolio.
The players
EmeraNova
A Phoenix-based company focused on amniotic membrane products and advanced research in surgery, sports medicine, and acute care.
BLS Labs, LLC
An AATB-accredited laboratory division responsible for technical research and development within the parent organization.
BLS Sales & Marketing, LLC
An AATB-accredited commercial arm focused on market expansion and business partnerships for the company's product lines.
The details
EmeraNova functions by identifying emerging technologies and accelerating them through a structured eight-stage path that spans from initial assessment to final tissue remodeling. By centralizing operations under the new name, the firm is positioning its existing amniotic membrane research for wider integration into acute care, vascular care, and surgical settings.
Timeline
October 15, 2026: BioLab Holdings announced its new identity as EmeraNova.
2026: The company completed four clinical trials and three published, peer-reviewed retrospective studies.
October 16-18, 2026: The company will showcase its new brand at the Symposium for Advanced Wound Care in Las Vegas.
Market Landscape
The rebranding marks a departure from a narrow chronic wound care focus, aligning the company more closely with high-growth surgical and sports medicine segments. This expansion follows the industry standard of showcasing new clinical capabilities at venues like the Symposium for Advanced Wound Care.
Operators in hospital outpatient and surgical departments should monitor EmeraNova’s expanded application list for potential new procurement options. Watch for updates on international distribution partnerships that could influence future supply chain logistics for amniotic membrane products.
The takeaway
The company’s shift to a broader clinical footprint reflects a strategy to diversify into acute and sports medicine settings. Review your current wound care vendor agreements for potential synergies as these providers expand their portfolios into surgical and outpatient care.
Further reading
Learn more about local industry movements in the Healthcare section.
